News & Updates

Show Multimedia Only

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

02 Apr 2026

At the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore, results of a retrospective cohort study that evaluated first-line panitumumab- vs cetuximab-based therapy in patients with newly diagnosed RAS wild-type metastatic colorectal cancer (mCRC) were reported. The analysis focused on overall survival (OS) and metastatic-site resection rates, providing valuable real-world insights into treatment selection beyond traditional survival endpoints.

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

02 Apr 2026

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

01 Apr 2026 by

The highly selective colony-stimulating factor-1 receptor inhibitor pimicotinib demonstrates robust antitumour activity in patients with tenosynovial giant cell tumour, yielding meaningful improvements in physical function and symptom burden with a manageable safety profile, according to the international phase III MANEUVER trial.

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

01 Apr 2026

One-time screening in never-smokers a game-changer in lung cancer

01 Apr 2026 by

Data from a large, prospective, non-randomized study in China show that one-time low-dose computed tomography (LDCT) screening is associated with a significant reduction in lung cancer mortality in a non–risk-based population, including those who have never smoked.

One-time screening in never-smokers a game-changer in lung cancer

01 Apr 2026

Metformin may protect against esophageal squamous cell carcinoma

31 Mar 2026

Metformin users appear to have a reduced risk of esophageal squamous cell carcinoma (ESCC) compared with nonusers, as shown in a population-based study.

Metformin may protect against esophageal squamous cell carcinoma

31 Mar 2026

2-year data support nerve-sparing technique in prostate cancer surgery

27 Mar 2026 by

An updated 24-month analysis of the NeuroSAFE PROOF study continues to support robot-assisted radical prostatectomy (RARP) guided by the nerve-sparing NeuroSAFE technique in men with prostate cancer.

2-year data support nerve-sparing technique in prostate cancer surgery

27 Mar 2026

Pre-TURBT mitomycin-C improves RFS in NMIBC

26 Mar 2026 by

In the updated 5-year analysis of a randomized phase II trial, administering two doses of intravesical mitomycin-C (MMC) immediately before transurethral resection of bladder tumour (TURBT) improves recurrence-free survival (RFS) in individuals with non-muscle invasive bladder cancer (NMIBC).

Pre-TURBT mitomycin-C improves RFS in NMIBC

26 Mar 2026

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

24 Mar 2026

The 2025 guidelines set by the American Urological Association (AUA) improve stratification of patients with microscopic hematuria (MH) into risk groups for urothelial cancer, but not renal cortical neoplasms of any kind, according to a study.

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

24 Mar 2026

Enzalutamide improves outcomes in prostate cancer with hrBCR

24 Mar 2026 by

Treatment with enzalutamide monotherapy demonstrates numerically higher overall survival (OS) in prostate cancer patients with high-risk biochemical recurrence (hrBCR) when compared with leuprolide alone, but the difference is not statistically significant, as shown by the results of the EMBARK study.

Enzalutamide improves outcomes in prostate cancer with hrBCR

24 Mar 2026

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

23 Mar 2026

Premenopausal breast cancer patients who are receiving tamoxifen as adjuvant hormone therapy appear to be at increased risk of uterine diseases, including endometrial cancer, according to a target trial emulation study from Taiwan.

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

23 Mar 2026

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Solid organ transplant (SOT) recipients with a history of cancer are at increased risk of post-transplant cancer, especially the same type of cancer, according to a study.

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

One-time screening in never-smokers a game-changer in lung cancer

One-time screening in never-smokers a game-changer in lung cancer

Metformin may protect against esophageal squamous cell carcinoma

Metformin may protect against esophageal squamous cell carcinoma

2-year data support nerve-sparing technique in prostate cancer surgery

2-year data support nerve-sparing technique in prostate cancer surgery

Pre-TURBT mitomycin-C improves RFS in NMIBC

Pre-TURBT mitomycin-C improves RFS in NMIBC

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

Enzalutamide improves outcomes in prostate cancer with hrBCR

Enzalutamide improves outcomes in prostate cancer with hrBCR

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

Malignant disease may re-emerge following SOT among cancer survivors

Malignant disease may re-emerge following SOT among cancer survivors